Setting standards in one of the world's most challenging markets: ZEISS is on display at the WOC in Tokyo with innovations for ophthalmic surgery

JENA/TOKIO, Germany, 01.04.2014.

ZEISS will introduce two products to an international audience at this year's World Ophthalmology Congress (WOC) in Tokyo: as the market leader in surgical microscopes, ZEISS is presenting the first system for integrated intraoperative OCT imaging. The ZEISS portfolio for refractive surgery has been enriched with the addition of a new excimer laser, which covers the most challenging customer needs through its versatility and the minimally invasive SMILE technique.

One of the highlights at the event will be a new ZEISS system for ophthalmic surgery. It is comprised of the OPMI LUMERA® 700 surgical microscope and the integrated RESCAN™ 700 OCT camera. Initial treatment results have already been discussed at events in Vienna and Mainz. The system will be introduced to an international audience for the first time in Tokyo.

Pilot users unanimously reported that this system enabled them to recognize anatomical details vital to the success of the procedure without having to interrupt the operation. The system allows them to seamlessly monitor the surgery and to check the clinical outcomes directly. "The initial positive reports confirm our approach of setting new standards with the integration of two powerful technologies to enable even better treatment outcomes for our customers," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. The development of the system incorporated ZEISS' years of expertise in OCT technology. During the 1990s, the company developed OCT technology together with scientist James Fujimoto from the Massachusetts Institute of Technology (MIT), thus opening up entirely new methods for the treatment of eye diseases.

Another result of the company's years of experience in ophthalmology in the field of cataract surgery is the ZEISS Cataract Suite markerless. This solution provides cataract surgeons with a smooth workflow for the implantation of a toric intraocular lens. The eye is first measured with the IOLMaster® 500 optical biometer, the astigmatism axis determined and the intraocular lens selected. In the same step, the system takes a reference photo of the limbal blood vessels. This image is shown to the surgeon in the microscope during the procedure. The time-consuming manual marking of the astigmatism axis required in conventional methods is no longer needed.

Another innovation has been added to the FORUM® data management system from ZEISS: the FORUM Glaucoma Workplace review and analysis extension enables better visualization of the clinical data and thus more transparent patient consultation and education. The extension was launched on the US market at the end of 2013 and can now be introduced in Japan at the WOC. The application allows the display and analysis of data from the Humphrey® Field Analyzer (HFA) away from the system – virtually anywhere in the office. The interactive, functional Guided Progression Analysis™ system enables visualization of the acute progression of a patient's illness. A trend analysis allows doctors to better predict the further progression, particularly in patients who have a higher risk of subsequent damage to their visual field. The single HFA-CIRRUS report combines the examination data from the HFA and CIRRUS to enable better interpretation. ZEISS therefore particularly helps eye care professionals who use more than one Perimeter or Cirrus OCT. ZEISS also offers a tailored data management system for smaller practices: the preconfigured FORUM GO package. It allows eye care professionals to quickly and efficiently review examination results, diagnostic analysis and reports.

With the new MEL® 90 excimer laser and the trend-setting VisuMax® femtosecond laser, ZEISS is highlighting in Tokyo its unique product portfolio for refractive surgery. In addition to LASIK and femto-LASIK, ZEISS instruments enable methods of surface ablation such as photorefractive keratectomy (PRK) and LASEK. Furthermore, ZEISS is the worlds only manufacturer of medical equipment to offer the SMILE procedure (SMall Incision Lenticule Extraction) for laser vision correction. This method does not require a flap and has now been successfully established on the market in more than 80,000 operations. While the product has already been approved for Europe and most Asian countries, a study with promising results is underway in the USA. The study was expanded in December 2013 by the FDA to cover myopia up to -10 diopters.

The ZEISS activities at the WOC are rounded off by products from the extended basic diagnostic portfolio: VISULENS™ 500, the automatic focimeter from ZEISS determines easily and quickly the power of eyeglass lenses and contact lenses. The SL Cam 5.0 slit lamp imaging module is compatible with all ZEISS slit lamps and delivers high-quality images and videos.

"ZEISS has been present in Japan for more than 100 years. It is one of the key markets for Medical Technology products. With our products, we are setting new standards in this highly innovative environment," says Dr. Ludwin Monz.

Note to editors: ZEISS can be found at the WOC at booth E11 in the Exhibition Forum. ZEISS will host the press at the WOC on Friday, 4 April 2014 from 4-6 p.m. For more information and registration, please go to press .meditec @zeiss .com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.